Biomarkers Market

Biomarkers Market Research, 2034

Biomarkers Market is anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 13.1% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 64.3 billion and is projected to reach USD 249.6 billion by the completion of 2034.

Biomarkers are measurable indicators of biological states or conditions within an organism and serve as valuable tools in medical fields. These indicators can be genes, characteristics, or procedures that signify normal or abnormal function or the progression of a disease. Biomarkers offer important data about a person's health and are used in disease diagnosis, risk evaluation, and personalized medication. They can be found using imaging methods and in a variety of biological samples, such as blood, urine, and tissue. Thus, biomarkers are important for the development of healthcare and the improvement of patient outcomes as they allow for earlier identification and more precise diagnoses.

Market Highlights

Biomarkers Market is expected to grow at a compound annual growth rate (CAGR) of 13.1% from 2024 to 2034

Biomarkers Market is projected to reach USD 249.6 billion over the forecast period, owing to growing demand for personalized medicine and a high incidence of chronic diseases. The growth of the biomarkers market is further driven by high funding in pharmaceutical and biotech research, as well as an increase in healthcare spending. Additionally, the market is expanding due to the discovery of new biomarkers in the genomics, proteomics, and metabolomics segments. These biomarkers are classified based on various criteria like safety, efficacy, and predictive biomarkers. They are used in various medical domains such as brain disorders, cancer, and heart disease. However, despite the growth potential, challenges like high development costs and strict laws and regulations exist. Thus, the biomarkers market is predicted to expand due to its use in drug development and clinical diagnostics, which highlights its importance in offering healthcare solutions.

Source: Fatpos Global

Biomarkers Market Segmentation

Safety Technologies segment will lead the industry as it helps in finding potentially hazardous biomarkers

Biomarkers Market is classified based on the Type into Safety, Efficacy, and Validation. The safety segment dominates the biomarkers market as it is focused on finding biomarkers that signal possible hazards related to the development of medications and clinical trials. Safety biomarkers play an important role in verifying the safety of new treatments for patients before their approval for usage. Moreover, it helps in the early detection of adverse side effects, which is important for the safety of patients and regulatory compliance. As a result, pharmaceutical and biotechnology companies make large expenditures on safety biomarkers to reduce risks and ensure the safety of drugs. Thus, the focus on safety has fueled the growth of the safety segment, outpacing the effectiveness and validation sectors.

Consumables segment will lead the market due to its importance for conducting biomarker analysis and testing

Biomarkers Market is divided by Product Type into Consumables, Services, and Software. The consumables segment holds the largest share in the biomarkers market as consumables are comprised of products such as test kits, reagents, and other necessary materials for conducting biomarker analysis and testing. The growth in this segment is driven by the high need for regular diagnostic tests and the requirement to restock these supplies. Also, a higher emphasis on early disease detection has boosted the growth of consumables in healthcare practices. These products play an important role in a variety of applications, such as research and drug development. Furthermore, this segment leads the biomarkers market due to the continuous need for consumables in routine medical testing and research.

Source: Fatpos Global

Market Dynamics

Growth Drivers

Rising Prevalence of Chronic Diseases is Driving Growth in the Biomarkers Market

Increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders is boosting the demand for biomarkers. Biomarkers are vital for monitoring diseases, and their early detection, and offer personalized treatment procedures. As a result, healthcare practitioners are increasingly depending on biomarkers to improve the outcomes of patients and customize therapies as these disorders are diagnosed in an increasing number of people. Therefore, the market is growing due to the growing demand for accurate and reliable biomarkers, which also encourage investment in the invention of new technologies and instruments for diagnosis.

Advancements in Technology Act as a Catalyst for Market Growth

Technological breakthroughs, such as genomics, proteomics, and digital health, are helping to propel the growth of the biomarkers market. High-throughput sequencing and advanced imaging techniques are examples of innovations that improve the discovery and applications of biomarkers. These technical developments allow for more accurate and fast analysis, thus making it easier to detect biomarkers that are associated with particular diseases. Hence, as technology continues to improve, the scope and efficacy of biomarker-based diagnostics will also expand, thereby boosting the global biomarkers market.

Restraints

High Costs of Development in the Market Will Impact the Growth

Developing and confirming biomarkers can be expensive as well as time-consuming. The research and clinical trials required to prove the reliability and accuracy of biomarkers demand huge financial commitment. This cost can be prohibitive for many businesses, such as smaller corporations, and limit their access to advanced biomarker tests. Furthermore, the complications of the regulatory approval procedure increase costs and delays, which can impede the fast development and commercialization of new biomarkers. These issues can hinder the introduction of new biomarkers and limit their availability, thus impacting the growth of biomarker-based diagnoses and therapies.

Recent Developments

• In June 2024, Thermo Fisher expanded its biomarker discovery and validation capabilities through its acquisition of The Binding Site Group, enhancing its immunoassay and diagnostic products.
• In April 2024, Roche Diagnostics launched the Elecsys® Anti-SARS-CoV-2 S antibody test to support COVID-19 vaccination monitoring and has been developing novel biomarkers for oncology and cardiovascular diseases.
• In March 2024, Abbott enhanced its VeriSeq NIPT Solution for non-invasive prenatal testing, improving accuracy in detecting genetic abnormalities through biomarkers in maternal blood.
• In May 2024, Illumina launched the NovaSeq X Series, expanding its genomic sequencing capabilities for comprehensive biomarker discovery, including cancer genomics and rare genetic disorders.
• In July 2024, Qiagen introduced new molecular diagnostics platforms, including the NeuMoDx™ 288 and 96 Systems, enabling rapid and high-throughput testing for infectious diseases and oncology biomarkers.

Biomarkers Market: Key Players

• Thermo Fisher Scientific Inc.
• Roche Diagnostics
• Abbott Laboratories
• Siemens Healthineers
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• GE Healthcare
• Agilent Technologies, Inc.
• Illumina, Inc.
• Qiagen N.V.
• Merck KGaA
• PerkinElmer, Inc.
• Bruker Corporation
• BD (Becton, Dickinson, and Company)
• Hologic, Inc.
• Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)

Regional Analysis

Biomarkers Market is segmented based on regional analysis into five key regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North American region is leading the biomarkers market due to its advanced healthcare infrastructure, large expenditure in R&D, and high prevalence of chronic diseases. The region benefits due to strong medical research facilities, along with a high level of technology adoption and massive funding for new biomarker research. Moreover, strong regulatory support and well-established healthcare systems also help in encouraging growth across the North American region.

On the contrary, Europe is expected to experience momentous growth in the upcoming decade as a result of higher investments in healthcare innovation and a growing focus on personalized medicine. European nations are strengthening their research skills and upgrading healthcare systems to simplify the development and integration of leading biomarker technologies. Furthermore, it is anticipated that positive government actions and partnerships will improve market growth in the European region.

Source: Fatpos Global

Impact of COVID-19 on the Biomarkers Market

Biomarkers market has been greatly impacted by the COVID-19 epidemic. The pandemic initially increased demand for COVID-19 diagnostic biomarkers, such as assays for virus detection and immune response monitoring. However, the epidemic also caused supply chain disruptions and postponed several R&D projects. Furthermore, funding and attention were diverted from other fields of biomarker research in favor of the COVID-19 study. However, the pandemic accelerated the integration of digital health solutions and highlighted the need for prompt and accurate diagnosis. This shift is expected to promote growth and innovation in the biomarkers market, as the lessons learned from COVID-19 are influencing both present and future research.

Biomarkers Market is further segmented by region into:

• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and the Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

Biomarkers Market Scope and Segments:

Frequently Asked Questions (FAQ):